Teva executive Eric Hughes sells $367,287 in stock

Published 06/03/2025, 22:14
© Reuters

Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical (TASE:BLWV) Officer at Teva Pharmaceutical (TADAWUL:2070) Industries Ltd. (NYSE:TEVA), has recently sold a significant portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Hughes sold a total of 23,251 ordinary shares over two days.

On March 4, Hughes sold 15,174 shares at a weighted average price of $15.7346, while on March 5, he sold an additional 8,077 shares at a weighted average price of $15.9132. The total value of these transactions amounted to $367,287. While the stock has shown a 17.5% return over the past year, InvestingPro data suggests the shares are currently in oversold territory.

These sales were executed under a Rule 10b5-1 trading plan that Hughes adopted on November 15, 2024. Following these transactions, Hughes no longer holds any shares in the company. This activity is part of a broader pattern of executive stock transactions at Teva, and investors may wish to monitor such filings for future insights into insider trading activities. According to InvestingPro, analysts maintain a positive outlook with price targets ranging from $18 to $30, and the company is expected to return to profitability this year. Discover more insights and 6 additional ProTips with an InvestingPro subscription.

In other recent news, Teva Pharmaceutical Industries Ltd. reported fourth-quarter earnings that exceeded analyst expectations, with adjusted earnings per share of $0.71, surpassing the consensus estimate of $0.69. Revenue also beat projections, reaching $4.23 billion against an anticipated $4.1 billion. Despite this, Teva’s 2025 outlook disappointed investors, with projected earnings per share of $2.35-$2.65, falling short of the $2.78 consensus, and revenue forecasts of $16.8-17.4 billion compared to the expected $17.09 billion.

Additionally, BofA Securities adjusted its financial outlook for Teva, reducing the stock price target to $20 from $23 while maintaining a Buy rating. This adjustment reflects revised expectations for Teva’s future earnings, particularly concerning its generic version of Revlimid. In another development, the FDA accepted a supplemental New Drug Application for UZEDY, a long-acting injectable for bipolar I disorder, which Teva co-developed with Medincell.

Moreover, Teva reached a settlement agreement with Axsome Therapeutics (NASDAQ:AXSM), resolving patent litigation over the drug AUVELITY®, allowing Teva to sell a generic version starting in 2038 or 2039. Despite these varied developments, BofA Securities remains optimistic about Teva’s future product cycles, citing upcoming high-value product launches.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.